Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2600129872Phase 4Not yet recruiting
Phase 4, randomised trial of remimazolam in Not applicable (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Dosage of remimazolam per unit time. Planned start Aug 2026; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2600129872.